Hematology News

A moderate-intensity exercise regimen appeared to improve skeletal muscle microvasculature among patients with sickle cell disease, according to results of a randomized trial published in Blood.

The FDA approved crizanlizumab to reduce the frequency of pain crises among people with sickle cell disease.

A pivotal trial designed to assess KD025 for patients with pretreated chronic graft-versus-host disease met its primary endpoint of overall response rate, according to results from a planned interim analysis.

Use of selective and nonselective serotonin reuptake inhibitors appeared associated with a small increased risk for subdural hematoma, according to results of a nationwide, case-control study.

The FDA today approved luspatercept-aamt to treat anemia in adults with beta-thalassemia who undergo regular red blood cell transfusions.

The FDA office that reviews applications for cancer therapies has been renamed and reorganized.

ASH announced the election of three clinicians to leadership positions within the society.

The National Academy of Medicine announced the election of 90 regular members and 10 international members.

ASH will posthumously honor former society President Stanley L. Schrier, MD, with this year’s Exemplary Service Award.

Beth H. Shaz, MD, has started her 2019-2020 term as president of AABB.